

Topical presbyopia treatment study enrolls first patient

The first patient has been enrolled in the phase 1 and 2 study investigating EV06, a topical ophthalmic solution to treat presbyopia, developer Encore Vision (Forth Worth, Texas) said in a press release.

EV06 is a first-in-class proprietary lipoic acid choline ester compound that targets a biochemical cause of presbyopia, believed to be associated with an increase in the formation of disulfide bonds between the crystalline proteins within lens fiber cells. EV06 is intended to increase lens flexibility by breaking these bonds, thereby restoring elasticity, allowing the lens to focus on nearby objects. EV06 is a prodrug that penetrates the cornea and is subsequently broken down into lipoic acid and choline, two naturally occurring substances.

The prospective, randomized, double-masked, multicenter study will compare the safety and efficacy of EV06 to placebo in subjects 45 to 55 years of age with presbyopia. The 90-day study will aim to enroll 72 subjects and evaluate mean change in distance corrected near visual acuity and best corrected distance visual acuity, along with additional secondary outcomes.